Moderna has patented a method for creating messenger RNA (mRNA) with specific untranslated regions (UTRs) derived from naturally abundant mRNAs in tissues. The mRNA contains an open reading frame (ORF) encoding a protein, flanked by heterologous UTRs from genes like Haptoglobin and Complement Component 3. GlobalData’s report on Moderna gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Moderna, mRNA delivery lipid nanoparticles was a key innovation area identified from patents. Moderna's grant share as of May 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Moderna inc patent for mrna with heterologous utrs
A recently granted patent (Publication Number: US11980672B2) discloses a messenger RNA (mRNA) that encodes a protein, with the open reading frame (ORF) flanked by a heterologous 5' untranslated region (UTR) and/or a heterologous 3' UTR. The 5' UTR and/or the 3' UTR are derived from specific genes such as Haptoglobin (HP), Haptoglobin-Related Protein (HPR), Complement Component 3 (C3), and others. Additionally, the mRNA may contain modified or non-naturally occurring nucleotides, including various base modifications like N1-methyl-pseudouridine 5' triphosphate.
Furthermore, the mRNA described in the patent includes a therapeutic gene as the ORF, with options such as interferon alpha, TNF related apoptosis-inducing ligand, and hepatocyte growth factor. The mRNA can have a heterologous 5' UTR derived from genes like HP, FGB, HPR, and others, with specific nucleotide sequences mentioned in the claims. This innovative mRNA design aims to enhance protein expression and potentially improve therapeutic outcomes, offering a novel approach in the field of genetic engineering and mRNA-based therapies.
To know more about GlobalData’s detailed insights on Moderna, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
